Navaris Medical

Navaris Medical is a Swiss biotechnology company focused on developing next-generation cancer immunotherapies using a proprietary bacterial vector platform. The company utilizes live-attenuated Salmonella strains to deliver tumor-specific antigens directly to the immune system, aiming to trigger a robust and targeted anti-tumor response. Their approach combines the natural immunostimulatory properties of bacteria with precise genetic engineering to address various solid tumor types. Navaris is currently advancing its lead programs through preclinical development with the goal of entering clinical trials. Headquartered in Basel, the company is a spin-off from the University of Basel and is supported by specialized life science investors.